REPLY
13.12.2022 09:31:35 CET | Business Wire | Press release
POLIMI Graduate School of Management, Politecnico di Milano’s business school, and Reply, a company that has made innovation and technological specialisation its flagship, join forces to create a training path for excellence, which is aimed at preparing the professionals the industry needs to face future challenges.
Enrolment is now open for POLIMI Graduate School of Management Master's in "Digital Finance", which aims to offer highly qualified students a professional specialisation in financial services (fintech and insurtech) with a practical and experiential approach to innovation and new technologies such as: Artificial Intelligence, Machine Learning and Cloud.
The postgraduate course will start in April 2023 and will last 18 months. The Master’s includes a series of introductory courses on Business Management and Financial Services followed by a specialisation course aimed at training technical experts in the latest digital technologies (e.g. Cloud, AI, ML, etc.) applicable to the Financial Services market.
The lessons will be held online based on an executive model (lesson delivery will be on Fridays and Saturdays, for approximately 2 weekends per month) and the professors will be a mix of POLIMI Graduate School of Management academics and Reply specialists to combine theoretical lessons, workshops, hackathons and projects. The course will also include face-to-face meetings (2 or 3 over the course of the programme) at Politecnico di Milano laboratories or Reply offices. In the final stage of the course, students will carry out a 6-month work project at Reply, where they will put into practice the knowledge acquired in the classroom working in groups on live projects. The entire course is in English and open to international candidates.
The Master’s, at its first edition, is aimed at students with a Bachelor's or Master's degree in Computer Science, Computer Engineering, Cybersecurity, Automation Engineering, Electronics Engineering and Telecommunication Engineering which must be achieved by 31 March 2023 for three-year degrees, or by 31 July 2023 for Master's degrees.
Reply has committed to hire all candidates who are successful in their application and will bear the cost of the Master’s enrolment fees of those students who accept the job offer.
There are 50 places available and applications can be sent via the official website: master.reply.com. Applications will be accepted until all available places are filled, or until the deadline of March 13 2023.
More information available at master.reply.com.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
POLIMI GRADUATE SCHOOL OF MANAGEMENT
At POLIMI Graduate School of Management we create meaningful paths for future business leaders and the businesses they will lead, guided by the over-arching belief that we have a crucial role to play in shaping a better world for all. Based in Milan, Italy’s main business centre, our school was created over 40 years ago as MIP Politecnico di Milano and today it is a not-for-profit Consortia Limited Company composed of the University and a group of leading Italian and multinational companies. We offer more than 40 masters degrees, including MBA and EMBA, and a catalogue of over 200 open programmes, along with customised training for companies. We continue to innovate and our digital learning systems allow us to seamlessly integrate personalized and continuous learning experiences into our programmes and have placed us amongst the top-ranked Online MBA rankings globally. As part of the School of Management of Politecnico di Milano, we are among the few “Triple Crown” accredited schools across the world. With over 15,000 alumni and 3,000 students every year we are an innovative and entrepreneurial community made up of diverse people and partners. We see the power of relationships as a constant source of enrichment, innovation and inspiration, personal and professional. At POLIMI Graduate School of Management we take sustainability seriously and continue to work towards a better, more conscious, more equitable and more inclusive future. In 2020 we were the first European Business School to become a B Corp certified business. www.gsom.polimi.it/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005091/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom